In this issue:
The schizophrenia syndrome, circa 2024
Managing cardiac risks in patients taking antipsychotics
LAI antipsychotics vs oral antipsychotics in preventing psychiatric rehospitalisations
Evaluating monitoring guidelines of clozapine-induced adverse effects
Comprehensive evaluation of 45 augmentation drugs for schizophrenia
Newron TRS study 6 months’ results
Positive data with oral weekly risperidone (LYN-005)
Brilaroxazine shows promise for schizophrenia in pivotal phase 3 trial
FDA accepts new drug application for xanomeline-trospium (KarXT)
FDA Breakthrough Device designation for PDT
Australian early psychosis collaborative consortium
Best practice in working with people with mental health problems on probation
COVID-19 resources
Conferences, workshops and CPD
Please login below to download this issue (PDF)